Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
Determine wether 24 months treatment with everolimus prolongs progression free survival rate
(based on a central assessment) after embolisation ou chemoembolisation for liver metastases.
- H0 a 24 months progression free survival rate less than 35% is unacceptable
- H1 a 24 months progression free survival rate greater than 35% would show that
everolimus treatment is beneficial, the expected 24 months progression free survival
rate being 50%